{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-057679","form_type":"8-K","ticker":"A","cik":"0001090872","company_name":"AGILENT TECHNOLOGIES, INC.","filed_at":"2021-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.448386+00:00","generated_at":"2026-06-28T06:25:49.602986+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Agilent expands board to 12, appoints Dr. Otis Brawley, oncology expert","bullets":["Board expanded from 11 to 12 with appointment of Dr. Otis W. Brawley, effective Nov. 17, 2021.","Brawley will serve on Compensation and Nominating/Corporate Governance Committees.","He is Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.","Also serves on boards of Incyte Corp., Lyell Immunopharma, and PDS Biotechnology.","Receives standard non-employee director compensation, pro-rated for remainder of 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-057679","json":"https://secwatch.observer/filing/0001564590-21-057679.json","markdown":"https://secwatch.observer/filing/0001564590-21-057679.md","text":"https://secwatch.observer/filing/0001564590-21-057679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1090872/000156459021057679/0001564590-21-057679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1090872/000156459021057679/a-8k_20211117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T06:25:49.602986+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"882f30ceec","claim":"Otis W. Brawley was appointed as Director at AGILENT TECHNOLOGIES, INC..","evidence_excerpt":"increased the size of the Board from 11 to 12 members and appointed Otis W. Brawley, M.D., to fill the vacancy so created, both effective November 17, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1090872/000156459021057679/0001564590-21-057679-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}